FDA Brief

Warning letters Devices

FDA warning letter to

Avertix Medical, Inc.

High riskIssued Sep 3, 2025Posted Mar 17Center for Devices and Radiological Health

FDA warns Avertix Medical over Guardian implantable cardiac event detector quality violations and late injury reports.

What happened

FDA inspected Avertix's Eatontown, NJ facility from February 19, 2025, through March 11, 2025. It found the company did not properly handle or investigate complaints, did not reassess device risks after infections and battery failures, did not verify corrective and preventive actions (CAPA), did not address sterilization validation, and did not fully manage suppliers. FDA also found the company reported some serious injuries and malfunctions late or through voluntary MedWatch forms rather than required Medical Device Reporting (MDR) reports.

What FDA found

  1. The company did not maintain complaint files or follow procedures to review and investigate complaints, including infections that led to device removal.

    21 CFR 820.198(a), (a)(1), (c)
  2. The company's nonconforming product procedure did not require deciding whether an investigation was needed, and two nonconformances had no documented investigation.

    21 CFR 820.90(a)
  3. The company did not reassess device risks after observed infection and battery-failure rates were higher than the risk file estimates.

    21 CFR 820.30(g)
  4. The company did not follow its corrective and preventive action (CAPA) procedure and did not verify that several CAPAs were effective.

    21 CFR 820.100(a), (a)(4)
  5. The company's process validation procedures did not address sterilization validation or requalification for the implantable device.

    21 CFR 820.75(a)
  6. FDA says serious injuries from infections and malfunctions from early battery depletion were not reported within 30 calendar days as required.

    21 CFR 803.50(a)(1), 803.50(a)(2), 803.12(a)

What FDA wants

FDA asks Avertix to correct the cited quality-system and MDR violations, provide adequate corrective actions and supporting evidence, and conduct retrospective reviews; the provided letter does not state a response deadline.

Who should pay attention

  • makers of implantable cardiac monitors
  • medical device firms with complaint, CAPA, and MDR duties
  • companies relying on contract manufacturers and sterilization vendors

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  2. Peter Schiff Enterprises

    FDA warns Peter Schiff Enterprises over unapproved cardiac devices and serious quality system failures.

    High risk
  3. Chirp Innovations, LLC

    FDA warned Chirp Innovations over quality-system gaps, missing adverse-event reporting procedures, and unapproved marketing of its Halo muscle stimulator for menstrual pain.

    High risk
  4. Rohto Pharmaceutical Co., Ltd.

    FDA cites Rohto Vietnam eye-drop plant for falsified sterility records, poor aseptic practices, and unapproved Cooling Eye Drops.

    High risk